Sindhwani Deepanshu, Arora Kaushal, Kumar Pankaj, Verma Prabhakar Kumar, Bhosale Vivek V
Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Department of Pharmaceutical Sciences Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Curr Protein Pept Sci. 2025 Jun 18. doi: 10.2174/0113892037355750250526052851.
Molecular degraders represent a ground-breaking class of small molecules revolutionizing drug discovery through the selective elimination of disease-causing proteins, including those previously deemed "undruggable." This review provides a critical analysis of the design and mechanistic intricacies of molecular degraders, encompassing PROTACs, molecular glues, and SNIPERs, with a focus on their reliance on ubiquitin-mediated protein degradation pathways. Key themes include advancements in E3 ligase selection, the principles guiding ternary complex formation, and the role of structural dynamics in optimizing degrader activity and selectivity. The data for this review was collected from various databases such as Science Direct, United States National Library of Medicine (Pubmed), Google Scholar, Elsevier, Springer, and Bentham. Novel findings, such as the development of non-canonical degrader approaches and their preclinical successes, are examined alongside therapeutic applications in oncology, neurodegenerative diseases, and infectious disorders. Challenges, including resistance mechanisms, safety concerns, and pharmacokinetic limitations, are evaluated to provide a holistic perspective. This review not only highlights the transformative potential of molecular degraders but also identifies future directions and critical gaps that could drive innovation in targeted protein degradation and precision medicine.
分子降解剂代表了一类开创性的小分子,通过选择性消除致病蛋白(包括那些以前被认为“不可成药”的蛋白)彻底改变了药物发现。本综述对分子降解剂(包括PROTAC、分子胶和SNIPER)的设计和机制复杂性进行了批判性分析,重点关注它们对泛素介导的蛋白质降解途径的依赖。关键主题包括E3连接酶选择的进展、指导三元复合物形成的原则以及结构动力学在优化降解剂活性和选择性方面的作用。本综述的数据来自多个数据库,如科学Direct、美国国立医学图书馆(PubMed)、谷歌学术、爱思唯尔、施普林格和本特姆。研究了非经典降解剂方法的发展及其临床前成功等新发现,以及在肿瘤学、神经退行性疾病和感染性疾病中的治疗应用。评估了包括耐药机制、安全性问题和药代动力学限制在内的挑战,以提供全面的视角。本综述不仅强调了分子降解剂的变革潜力,还确定了未来的方向和关键差距,这些可能推动靶向蛋白质降解和精准医学的创新。